Clinical Trials Logo

Purpura, Thrombocytopenic clinical trials

View clinical trials related to Purpura, Thrombocytopenic.

Filter by:

NCT ID: NCT00907478 Completed - Thrombocytopenia Clinical Trials

Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)

Start date: August 11, 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate changes in bone marrow morphology (structure) after long-term exposure to romiplostim.

NCT ID: NCT00888901 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

PLATEFUN
Start date: May 2009
Phase: Phase 4
Study type: Interventional

This is a single-center, prospective, controlled study with one eltrombopag treatment group and 2 control groups, one on standard steroid treatment, and another one untreated. The aim of the study is to determine the effect of Thrombopoietin Receptor (MPL) agonists on shear-induced platelet activation.

NCT ID: NCT00861224 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology

Start date: August 2005
Phase: N/A
Study type: Observational

This study was conducted in conjunction with the 2 phase 3 studies of AMG 531 (20030105 and 20030212) and an open-label extension study (20030213) and compared pretreatment and posttreatment bone marrow samples for the purpose of studying morphologic changes.

NCT ID: NCT00860600 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura (ITP)

Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This was a phase II multi-center, randomized, open-label study with two parallel study groups to evaluate the efficacy and safety of PG2 in ITP patients.

NCT ID: NCT00828750 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Start date: May 2008
Phase: Phase 3
Study type: Interventional

An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).

NCT ID: NCT00799773 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

STAR
Start date: April 2009
Phase: Phase 3
Study type: Interventional

Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiveness of an antibody, rituximab, in combination with plasma exchange, at improving the immune response in people with TTP and decreasing the recurrence of TTP.

NCT ID: NCT00774202 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Start date: November 2003
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of Rituxan. Patients eligible for this protocol will be stratified into two subgroups according to their initial response to Rituxan.

NCT ID: NCT00770562 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00749112 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

Start date: August 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether the combination of low doses of alemtuzumab and rituximab are effective in the treatment of patients with autoimmune cytopenias who has failed on steroids, relapsed after steroids withdrawal or required continuous steroids treatment.

NCT ID: NCT00726544 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.